Kidney Transplant Rejection
📧 Sign up to get email alerts when something new happens for Kidney Transplant Rejection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-06-16FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for mycophenolate mofetil from Hikma Pharmaceuticals USA Inc. for the generic formulation.
-
FDA approval · 2019-12-13FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA label_change · 2019-12-13FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CellCept (mycophenolate mofetil hydrochloride) submitted by Genentech, Inc., influencing labelin…
-
FDA approval · 2019-11-27FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for mycophenolate mofetil submitted by Hikma Pharmaceuticals USA Inc. The approval may involve label…
-
FDA approval · 2019-11-25FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (CONCORD BIOTECH LIMITED)
The FDA approved a supplemental application for mycophenolate mofetil from Concord Biotech Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-11-22FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for a generic version of mycophenolate mofetil by Strides Pharma Science Limited. Indications includ…
-
FDA approval · 2019-11-18FDA Approved: TACROLIMUS — Supplemental Application (Jubilant Cadista Pharmaceuticals Inc.)
FDA approved Jubilant Cadista Pharmaceuticals Inc.’s supplemental application for tacrolimus, approving a generic tacrolimus product under a…
-
FDA approval · 2019-10-18FDA Approved: SIROLIMUS — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC for an original application of sirolimus (Rapamune), a generic form of rapamycin, to prevent …
-
FDA approval · 2019-10-04FDA Approved: TACROLIMUS — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for tacrolimus from Quallent Pharmaceuticals Health LLC, granting an additional regulatory action to…
-
FDA approval · 2019-09-17FDA Approved: TACROLIMUS — Supplemental Application (Sandoz Inc.)
The FDA approved a supplemental application for tacrolimus from Sandoz Inc., resulting in changes to the approved product, such as labeling …
-
CLINICAL_TRIALS trial_result · 2019-09-10Clinical Trial Update: Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients [Phase 4]
Phase 4 trial comparing belatacept to tacrolimus in deceased donor renal transplant recipients has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-07-11Clinical Trial Update: C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection [Phase 2]
Phase 2 trial update for C1-Inhibitor (INH) in refractory antibody-mediated rejection after kidney transplant; results have been posted.
-
FDA approval · 2019-06-11FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for Prograf (tacrolimus) filed by Astellas Pharma US, Inc. The action updates the labeling to re…
-
FDA approval · 2019-02-27FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) filed by Genentech, resulting in an approved change to the prod…
-
FDA approval · 2019-01-08FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (CONCORD BIOTECH LIMITED)
FDA approved the original application for mycophenolate mofetil (CONCORD BIOTECH LIMITED) for prevention of organ transplant rejection in ki…
-
CLINICAL_TRIALS trial_result · 2019-01-03Clinical Trial Update: Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation [Phase 4]
Phase 4 clinical trial comparing antithymocyte globulin with azathioprine to basiliximab with mycophenolate mofetil in living donor kidney t…
-
FDA approval · 2018-08-23FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation [Phase 4]
Phase 4 trial comparing alemtuzumab to anti-thymocyte globulin for prevention of graft rejection in kidney and pancreas transplantation; com…
-
FDA approval · 2018-05-24FDA Approved: PROGRAF — Original Application (Astellas Pharma US, Inc.)
FDA approves PROGRAF (tacrolimus) under the original application for prevention of organ transplant rejection in kidney, liver, and heart tr…
-
FDA approval · 2018-05-24FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for PROGRAF (tacrolimus) submitted by Astellas Pharma US, Inc.
-
FDA approval · 2018-04-13FDA Approved: NULOJIX — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for NULOJIX (belatacept) filed by E.R. Squibb & Sons, L.L.C. to update the product labeling.
-
CLINICAL_TRIALS trial_result · 2018-03-15Clinical Trial Update: Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes
Completed clinical trial evaluating anti-AT1 receptor antibodies and kidney transplant outcomes.
-
FDA approval · 2017-12-18FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Cellcept (mycophenolate mofetil) from Genentech, Inc., authorizing changes to the product’s …
-
FDA approval · 2017-11-30FDA Approved: TACROLIMUS — Original Application (BPI Labs LLC)
The FDA approved an original application for tacrolimus from BPI Labs LLC, authorizing a generic tacrolimus product to prevent organ transpl…
-
CLINICAL_TRIALS trial_result · 2017-11-08Clinical Trial Update: Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)
This clinical trial update reports completion of a pediatric study investigating how the renin-angiotensin system affects renal transplant i…